Metformin-loaded microsphere promotes an anti-tumour response through the caspase-mediated apoptotic pathway against MDA-MB-231 cells
Abstract
Metformin has been reported to have antidiabetic effects. Metformin also has anti-inflammatory and antibacterial activity. However, the target specificity remains the major problem regarding this. Therefore, as it lacks target specificity, nanoformulation or microsphere formulation of this compound might have a good chance of overcoming this problem. Thus, to overcome this problem, we have made a metformin-loaded microsphere that shows target-specific activity. Furthermore, the microsphere-loaded Metformin was administered to the EAC cell, MDA-MB-231. Results showed that the formulated drug was more potent against the MDA-MB-231 cell line. It shows dose-dependent inhibition in cell growth. For further evaluation, we investigated this matter and found that the drug-induced cytotoxicity is ROS-dependent and may occur through alterations in mitochondrial membrane potential. Additionally, this causes apoptotic marker proteins, such as cleaved PARP and cleaved caspase-3, to increase in expression. Overall, our data indicated that the formulated metformin was more effective than the free form in reducing cancer growth and enhancing survivability. Thus, the findings suggest that the formulated drug may be effective in reducing cancer growth and improving survivability.
Keywords:
Metformin, Microsphere, apoptosis, Reactive oxygen species (ROS)DOI
https://doi.org/10.25004/References
Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol. 2020;10(2):785–809.
Feng H, Shang S, Chen K, Sun X, Yue X. Impact of metformin on melanoma: a meta-analysis and systematic review. Front Oncol. 2024;14:1399693.
Wu H, Huang D, Zhou H, Sima X, Wu Z, Sun Y, et al. Metformin: a promising drug for human cancers (Review). Oncol Lett. 2022;24(2):204.
Misirkic Marjanovic MS, Vucicevic LM, Despotovic AR, Stamenkovic MM, Janjetovic KD. Dual anticancer role of metformin: an old drug regulating AMPK dependent/independent pathways in metabolic, oncogenic/tumor-suppressing and immunity context. Am J Cancer Res. 2021;11(6):2510–2535.
Nojima I, Wada J. Metformin and its immune-mediated effects in various diseases. Int J Mol Sci. 2023;24(1):755.
Pereira FV, Melo ACL, Low JS, de Castro ÍA, Braga TT, Almeida DC, et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 2018;9(18):25808–25.
Dowling RJO, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–12.
Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19(8):460–76.
Chen X, Qian Y, Wu S. The Warburg effect: evolving interpretations of an established concept. Free Radic Biol Med. 2015;79:253–63.
Porporato PE, Filigheddu N, Pedro JMBS, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–80.
LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77–96.
Chakra BK, Karan S, Das B, Debnath S, Chatterjee TK. A controlled release microsphere formulation of an anti-diabetic drug and characterization of the microsphere. Int J Pharm Pharm Sci. 2018;10(10):30–38.
Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: systematic review and meta-analysis. PLoS One. 2012;7(3):e33411.
Dowling RJO, Goodwin PJ, Stambolic V. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31–43.
Chakra BK, Karan S, Das B, Debnath S, Chatterjee TK. A controlled release microsphere formulation of an anti-diabetic drug and characterization of the microsphere. Int J Pharm Pharm Sci. 2018;10(10):30–38.
Chakra BK, Debnath S, Mukherjee A, Kuotsu K, Chakraborty M, Kumar T, et al. Potent anti-diabetic activity of polymeric microsphere formulated metformin on streptozotocin-induced diabetic rat model. Int J Life Sci Pharma Res. 2022;12(2):68–81.
Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9(6):304–16.
Rizwanullah M, Ahmad N, Ali A, Amin S, Mir SR. Metformin-loaded chitosan nanoparticles to improve cellular uptake and antiproliferation activity against breast cancer cells. Colloids Surf B Biointerfaces. 2016;140:483–91.
Wang Y, Sun S, Zhang Z, Shi D, Zhang X. Metformin-loaded PLGA nanoparticles suppress breast cancer cell growth by activating AMPK pathway. Int J Pharm. 2019;558:217–28.
Chakra BK, Karan S, Das B, Debnath S, Chatterjee TK. A controlled release microsphere formulation of an anti-diabetic drug and characterization of the microsphere. Int J Pharm Pharm Sci. 2018;10(10):30–38.
Wilson CH, Kumar S. Caspases in metabolic disease and their therapeutic potential. Cell Death Differ. 2018;25(6):1010–21.
Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ. 2015;22(4):526–39.
He L, Wondisford FE. Metformin action: concentrations matter. Nat Med. 2015;21(2):112–4.
Zhang W, Yu X, Feng Q, Chen Y, Xie Y, Wang H, et al. Microsphere-based delivery systems for targeted cancer therapy: recent advances and challenges. Adv Drug Deliv Rev. 2021;174:39–58.
Published
Abstract Display: 31 How to Cite
Issue
Section
Copyright (c) 2025 Biplab Chakra, Souvik Debnath, Avinaba Mukherjee, Sudipto Datta, Tapan Kumar Chatterjee
This work is licensed under a Creative Commons Attribution 4.0 International License.
